Safety of long-term monthly cycles of methylprednisolone in combination with interferon β-1a IM in treatment-naive early relapsing-remitting multiple sclerosis patients in the MECOMBIN trial

被引：0
|
作者：
Ravnborg, M.
Sorensen, P. S.
Andersson, M.
Celius, E. Gulowsen
Jongen, P.
Batholome, E.
Elovaara, I.
Beer, K.
Sperling, B.
机构：
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 50 条
  • [21] Alemtuzumab reduces disease activity in treatment-naive patients with highly active relapsing-remitting multiple sclerosis
    Krieger, S.
    Lubetzki, C.
    Palmer, J.
    Margolin, D. H.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 106 - 107
  • [22] Glatiramer acetate in treatment-naive and immunomodulatory pre-treated relapsing-remitting multiple sclerosis patients
    Baumhackl, Ulf
    Pantev, Marina
    Klasser, Manfred
    MULTIPLE SCLEROSIS, 2008, 14 : S31 - S31
  • [23] Serum Leptin Levels in Treatment-Naive Patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
    Evangelopoulos, Maria Eleftheria
    Koutsis, Georgios
    Markianos, Manolis
    AUTOIMMUNE DISEASES, 2014, 2014
  • [24] Quality of life assessment of relapsing-remitting multiple sclerosis patients on long-term treatment with Betaferon
    Davidescu, I.
    Damian, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 129 - 129
  • [25] Radiological Evidence for the Long-Term Effect of Fingolimod Treatment in Patients with Relapsing-Remitting Multiple Sclerosis
    Cohen, Jeffrey
    Tenenbaum, Nadia
    Bhatt, Alit
    Pimentel, Ron
    Kappos, Ludwig
    NEUROLOGY, 2017, 89 (08) : E103 - E103
  • [26] Nordic trial of methylprednisolone as add-on therapy to interferon-beta for the treatment of relapsing-remitting multiple sclerosis
    Sorensen, Per Soelberg
    Frederiksen, Jette L.
    Myhr, Kjell-Morten
    Beiske, Antonie
    Mellgren, Svein I.
    Sandberg, Magnhild
    MULTIPLE SCLEROSIS, 2008, 14 : S299 - S300
  • [27] Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial
    Ravnborg, Mads
    Sorensen, Per Soelberg
    Andersson, Magnus
    Celius, Elisabeth G.
    Jongen, Peter J.
    Elovaara, Irina
    Bartholome, Emmanuel
    Constantinescu, Cris S.
    Beer, Karsten
    Garde, Ellen
    Sperling, Bjorn
    LANCET NEUROLOGY, 2010, 9 (07): : 672 - 680
  • [28] Continuous versus non-continuous subcutaneous interferon β-1a treatment in relapsing-remitting multiple sclerosis: long-term data from the PRISMS study
    Uitdehaag, B.
    Kappos, L.
    Verdun, E.
    Gardner, J.
    JOURNAL OF NEUROLOGY, 2009, 256 : S122 - S123
  • [29] Use of the FIM™ instrument in a trial of intramuscular interferon β-1a for disease progression in relapsing-remitting multiple sclerosis
    Granger, CV
    Wende, K
    Brownscheidle, CM
    AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2003, 82 (06) : 427 - 436
  • [30] Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
    Vazquez Gomez, Lazaro Aurelio
    Hidalgo Mesa, Carlos
    Broche Perez, Yunier
    Valdes Morales, Yanet
    MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2022, 20 (05): : 825 - 833
12345